Amgen Inc. (NASDAQ: AMGN) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight has published 2 articles on AMGN since April 30, 2026, most recently "Amgen (NASDAQ:AMGN) Posts Q2 2026 Beat, Raises Full-Year Revenue Outlook by $1B" on Tuesday, August 4, 2026. Coverage to date spans Earnings Report and Health Care, tracking AMGN's earnings, analyst activity, and material corporate events. New coverage is added each trading day.
Amgen's Q2 revenue rose 10% to $10.1B, with 22 products delivering double-digit growth and full-year guidance lifted to $38.8B at the midpoint.
Amgen shares slipped 0.46% as the FDA proposed withdrawing Tavneos approval. Q1 results are due imminently, with analyst consensus tilting toward Buy.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.
Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.